

# Fine tuning the extracellular environment accelerates the derivation of kidney organoids from human pluripotent stem cells

Elena Garreta<sup>1,13</sup>, Patricia Prado<sup>1,13</sup>, Carolina Tarantino<sup>1</sup>, Roger Oriá<sup>2,3</sup>, Lucia Fanlo<sup>4</sup>, Elisa Martí<sup>4</sup>, Dobryna Zalvidea<sup>5</sup>, Xavier Trepát<sup>5,6,7,8</sup>, Pere Roca-Cusachs<sup>2,3</sup>, Aleix Gavaldà-Navarro<sup>9</sup>, Luca Cozzuto<sup>10</sup>, Josep Maria Campistol<sup>11</sup>, Juan Carlos Izpisúa Belmonte<sup>12</sup>, Carmen Hurtado del Pozo<sup>1</sup> and Nuria Montserrat<sup>1,6\*</sup>

**The generation of organoids is one of the biggest scientific advances in regenerative medicine. Here, by lengthening the time that human pluripotent stem cells (hPSCs) were exposed to a three-dimensional microenvironment, and by applying defined renal inductive signals, we generated kidney organoids that transcriptomically matched second-trimester human fetal kidneys. We validated these results using ex vivo and in vitro assays that model renal development. Furthermore, we developed a transplantation method that utilizes the chick chorioallantoic membrane. This approach created a soft in vivo microenvironment that promoted the growth and differentiation of implanted kidney organoids, as well as providing a vascular component. The stiffness of the in ovo chorioallantoic membrane microenvironment was recapitulated in vitro by fabricating compliant hydrogels. These biomaterials promoted the efficient generation of renal vesicles and nephron structures, demonstrating that a soft environment accelerates the differentiation of hPSC-derived kidney organoids.**

Kidney organoids have been produced from human pluripotent stem cells (hPSCs) by specific induction of the metanephric mesenchyme (MM) lineage (including nephron progenitor cells, NPCs)<sup>1–7</sup>, or by the simultaneous induction of MM- and ureteric bud (UB)-like progenitors<sup>8,9</sup>, the two progenitor cell populations that give rise to the adult kidney during development. Recently, NPCs and UB progenitors were separately induced and then aggregated together into three-dimensional (3D) spheroids that generated kidney organoids with higher-order architecture<sup>10</sup>. For kidney organoids generated from human embryonic stem cells (hESCs), CRISPR/Cas9 technology can be used to recapitulate the molecular features of kidney diseases<sup>4</sup>. Human kidney organoids can also be used as unprecedented in vitro models to screen for nephrotoxicity<sup>3,4,9</sup>. Besides the importance of these findings, major concerns related to the lack of vascularization and insufficient maturation still require further investigation to advance the field of hPSC-derived kidney organoids (kidney organoids). Biophysical cues have been shown to regulate cell behaviour, including the stemness and differentiation of different stem cell populations. Recently, application of fluid flow enhanced hPSC-derived podocyte-like cell differentiation in monolayer culture<sup>11</sup>, and the modulation of adherent forces in kidney organoids, resulted in changes in

the functional performance of proximal tubular epithelial-like cells within kidney organoids<sup>12</sup>.

## Efficient generation of kidney organoids in 3D culture

During mammalian kidney development, the posterior primitive streak (PPS) and anterior primitive streak (APS) give rise to the intermediate mesoderm (IM) and definitive endoderm, respectively. The posterior IM generates the MM, whereas the anterior IM forms the UB. The PPS can be generated from hPSCs using a combination of growth factors (including BMP4)<sup>1,7,8</sup>, or by exposing undifferentiated cells to varying doses and durations of the Wnt signalling agonist CHIR99021 (CHIR), a widely used inhibitor of glycogen synthase kinase 3 (GSK3 $\beta$ )<sup>1–5,8,9</sup>. Building upon these observations, we asked whether PPS cells could be generated by exposing hPSCs to a high dose of CHIR (8  $\mu$ M) in two-dimensional monolayer culture over three consecutive days (Supplementary Fig. 1a; Methods). This treatment regimen was sufficient to induce PPS-committed cells that were positive for the PPS marker BRACHYURY (referred to as T), at  $82.2 \pm 2.6\%$  efficiency (Supplementary Fig. 1b,c). PPS-committed cells upregulated the expression of PPS genes in comparison with APS genes (Supplementary Fig. 1d). Subsequent exposure of PPS-committed cells to a combination of FGF9 and activin A

<sup>1</sup>Pluripotency for Organ Regeneration, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Technology (BIST), Barcelona, Spain.

<sup>2</sup>Cellular and Respiratory Biomechanics, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Technology (BIST), Barcelona, Spain.

<sup>3</sup>University of Barcelona, Barcelona, Spain. <sup>4</sup>Instituto de Biología Molecular de Barcelona (IBMB-CSIC), Parc Científic de Barcelona, Barcelona, Spain.

<sup>5</sup>Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Technology (BIST), Barcelona, Spain. <sup>6</sup>Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina, Barcelona, Spain. <sup>7</sup>Unitat de Biofísica i Bioenginyeria, Universitat de Barcelona, Barcelona, Spain.

<sup>8</sup>Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. <sup>9</sup>Departament de Bioquímica i Biomedicina Molecular, Institut de Biomedicina (IBUB), Universitat de Barcelona and CIBER Fisiopatología de la Obesidad y Nutrición, Barcelona, Spain. <sup>10</sup>Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain. <sup>11</sup>Hospital Clinic, University of Barcelona, IDIBAPS, Barcelona, Spain.

<sup>12</sup>Gene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, CA, USA. <sup>13</sup>These authors contributed equally: Elena Garreta and Patricia Prado.

\*e-mail: [nmontserrat@ibecbarcelona.eu](mailto:nmontserrat@ibecbarcelona.eu)

(20:1) for an additional day resulted in acquisition of the early IM marker PAX2 at  $85.0 \pm 1.4\%$  efficiency (Supplementary Fig. 2a–c; Methods). Accordingly, messenger RNA levels for the posterior IM markers *OSR1* and *HOXD11* and the anterior IM marker *GATA3* were also upregulated at this stage (Supplementary Fig. 2d).

We next reasoned that increasing the time that IM-committed cells are exposed to 3D culture, which increase cell-to-cell and cell-to-extracellular matrix interactions, would generate kidney organoids at higher efficiencies than previously reported<sup>3,8,9</sup>. Therefore, 3D spheroids were generated by the self-aggregation of IM cells and maintained under 3D organotypic culture until day 16 (Fig. 1a; see Methods). Treatment of IM-committed 3D spheroids (day 0) with CHIR (3  $\mu$ M) for 3 d (from day 0 to day 3), while maintaining FGF9 signalling (from day 0 to day 7), resulted in the formation of numerous renal vesicles (RVs) on day 8 (Supplementary Fig. 3a,b), which were analysed by immunofluorescence for RV-associated markers, including PAX2, WT1, LHX1, PAX8, HNF1 $\beta$ , ECAD and BRN1 (Supplementary Fig. 3a,c,d). Remarkably, *SIX2*-positive cells were absent on day 8, indicating the lack of MM progenitors at this stage (Supplementary Fig. 3d). In addition, downregulation of the epithelial-to-mesenchymal markers *TWIST* and *SNAIL* and upregulation of *WNT4* and *ECAD* coincided with initiation of the mesenchymal-to-epithelial transition, which is essential for nephrogenesis (Supplementary Fig. 3e). RV-stage organoids were then differentiated in the absence of growth factors (from day 7 to day 16). This resulted in the derivation of kidney organoids with multiple nephron-like structures that were segmented into typical nephron components, including proximal tubules (LTL<sup>+</sup> AQP1<sup>+</sup>/SLC3A1<sup>+</sup>), loops of Henle (ECAD<sup>+</sup> UMOD<sup>+</sup>), distal tubules (UMOD<sup>-</sup> ECAD<sup>+</sup>), and glomeruli (PODXL<sup>+</sup>/PODOCIN<sup>+</sup>/NEPHRIN<sup>+</sup>/NEPH1<sup>+</sup>/WT1<sup>+</sup> PODXL<sup>+</sup> LTL<sup>-</sup>/PODOCIN<sup>+</sup> LTL<sup>-</sup>) (Fig. 1b, Supplementary Fig. 4a–g). In addition, quantitative PCR (qPCR) and immunofluorescence analyses confirmed that isolated LTL<sup>-</sup> and LTL<sup>+</sup> cell fractions from day 16 organoids expressed markers of glomerular and proximal tubular identity, respectively (Supplementary Fig. 5a–f). Similarly, markers representative of the major steps of differentiation were analysed by qPCR (Supplementary Fig. 6). Our methodology was quite robust, as kidney organoids from two commercial hESclines and one human induced pluripotent stem cell (hiPSC) line were also generated (Supplementary Fig. 7a–d, Supplementary Fig. 8).


To gain insight into the sequence of transcription regulatory events necessary to promote renal differentiation from hPSCs, we performed RNA sequencing (RNA-Seq) analysis at major stages during the differentiation process. We compared our results with transcriptional data from human fetal organs/tissues from the first and second trimesters of gestation<sup>13,14</sup> (Supplementary Fig. 9, Supplementary Table 1; Methods), demonstrating that our technique specifically generated renal lineages. Importantly, RNA-Seq analysis showed that day 8 RV-stage organoids transcriptionally matched human fetal kidneys at 16 weeks of gestation, whereas day 16 kidney organoids matched human fetal kidneys at 22 weeks of gestation (Fig. 1c, Supplementary Table 2; Methods). We validated these findings by analysing markers of nephron progenitors (*SIX2*, *SALL1*, *PAX2*), the proximal tubular segment (*SLC3A1*) and the glomerular compartment (*NPHS1*, *PODXL*, *SYNPO*, *WT1*) via qPCR (Fig. 1d). Additionally, immunofluorescence analysis showed that localization of late-stage nephron markers was comparable between kidney organoids and human fetal kidney samples (Supplementary Fig. 4a–g). Transmission electron microscopy (TEM) analysis was performed on day 16 kidney organoids (Fig. 1e–j). Ultrathin sections revealed the presence of primitive podocyte-like cells with deposition of a basement membrane (Fig. 1g) and developing primary and secondary cell processes (Fig. 1h). Epithelial tubular-like cells with brush borders and high mitochondrial content were also detected (Fig. 1i,j).

## Kidney organoids recapitulate human kidney development


The formation of kidney organoids with segmented nephrons may depend on the existence of a transient population of NPCs responsible for the generation of nephron structures in vitro. We analysed by immunofluorescence the expression of *OSR1*, *WT1*, *PAX2* and *SIX2*, confirming that cells exhibiting a NPC signature were present in day 5 spheroids (Supplementary Fig. 10a,b). The posterior origin of NPCs was also confirmed by the detection of *HOXD11*, *OSR1*, and *WT1* mRNA by qPCR (Supplementary Fig. 10c). Interestingly, the anterior IM fate was also generated at this stage, as *GATA3* mRNA was detected (Supplementary Fig. 10c). We next evaluated the ability of day 5 NPCs to form kidney chimaeric structures ex vivo, taking advantage of a faithful reaggregation assay with mouse embryonic kidney cells<sup>15,16</sup>. After 6 d of culture, differentiated NPCs, identified by the expression of human nuclear antigen (HuNu), integrated into nascent nephron structures that expressed *WT1* in the glomerular segment and *PAX8* in the nascent nephron (Fig. 2a–f; Methods). Thus, day 5 NPCs exhibited the capacity to integrate into mouse nascent nephron structures, but not into the UB compartment, suggesting that the induction of UB derivatives from hPSCs may depend on additional exogenous signals. These results challenge previous findings<sup>9</sup> and agreed with a recent study that identified optimal time windows and exogenous signals for selectively inducing NPC and UB lineages from mouse and human PSCs<sup>10</sup>.

Next, we investigated the capacity of human kidney organoids to faithfully recapitulate complex nephron patterning events that have been mainly studied in the mouse model<sup>17</sup>. Day 8 RV-stage organoids were exposed to inhibitors of tankyrase (IWR1) and GSK3 $\beta$  (CHIR) to decrease or increase  $\beta$ -catenin signalling, respectively. CHIR treatment reduced the number of WT1<sup>+</sup> glomerulus-like structures when compared with vehicle (control) and IWR1. In contrast, the percentage of LTL<sup>+</sup> proximal tubule-like structures was unchanged (Fig. 2g,h). qPCR analysis confirmed a decrease in the expression of *WT1* and *PODXL* (proximal segment), and the induction of *WNT4* (a  $\beta$ -catenin target gene) in CHIR-treated organoids relative to control, whereas *PAX2* (whole nephron) remained unchanged (Fig. 2i). We next determined the effect of disrupting Notch signalling by treating day 8 RV-stage organoids with the  $\gamma$ -secretase inhibitor DAPT. Inhibition of Notch resulted in a severe loss of proximal tubule-like structures (LTL<sup>+</sup>), together with a reduction in *PODXL*<sup>+</sup> glomerulus-like structures when compared with control (Supplementary Fig. 11a,b). qPCR analysis confirmed the downregulation of proximal (*WT1*) and medial (*SLC3A1*) nephron segment markers (Supplementary Fig. 11c). These findings agree with the role of Notch signalling in specifying proximal and medial identity during nephron patterning in the mouse<sup>17</sup>, and expand previous knowledge about the effect of Notch signalling on kidney organoids<sup>3</sup>.

The kidney is a highly metabolic organ that generates ATP through oxidative phosphorylation. Into the light of this knowledge, we hypothesized that the energy metabolism profile of cells should be taken into account to promote the differentiation of hPSCs into renal subtypes. Therefore, we exposed day 8 RV-stage organoids to either cell culture medium that promotes glycolysis in stem cells<sup>18</sup> (endothelial cell growth medium, EGM) or cell culture medium favouring oxidative phosphorylation (renal growth medium (REGM) with insulin) for 8 d. Seahorse analysis revealed that REGM increased mitochondrial respiration in kidney organoids when compared with EGM (Fig. 2j–l), promoting an oxidative phosphorylation bioenergetic phenotype. Kidney organoids under REGM conditions enhanced tubule differentiation, as shown by the development of prominent proximal tubular structures (LTL<sup>+</sup>), more than with EGM (Fig. 2m,n), in agreement with previous findings<sup>19</sup>.



**Fig. 1 | Efficient generation of kidney organoids in 3D culture.** **a**, Schematic of the stepwise differentiation methodology for generating kidney organoids from hPSCs. **b**, Confocal microscopy images of glomerular structures in day 16 kidney organoids showing podocyte-like cells positive for PODXL, nephrin, NPH1 and podocin, and the basement membrane protein laminin. Scale bars, 25  $\mu\text{m}$ . **c**, Dendrogram representing the hierarchical clustering of day 0, 5, 8 and 16 kidney organoids with human fetal kidneys from 9, 13, 17 and 18 weeks of gestation (first trimester) and 22 weeks of gestation (second trimester). Data from Chuva de Sousa Lopes (SRP055513)<sup>13</sup> (1) and McMahon (SRP111183)<sup>14</sup> (2) are included in the analysis. **d**, qPCR analysis during kidney organoid differentiation and 13-, 16-, and 22-week human fetal kidneys (genes are indicated). Data are mean  $\pm$  s.d. For *SIX2*, *WT1*, *SALL1* and *PAX2*, day 0, day 5,  $n=3$ ; day 8, day 16,  $n=2$ . For *PODXL*, *SLC3A1*, *SYNPO* and *NPHS1*, day 0, day 5,  $n=1$ ; day 8, day 16,  $n=2$ . Each sample is a pool of six organoids. Three technical replicates are shown per sample. **e, f**, Semithin sections of day 16 kidney organoids showing glomerular (**e**) and tubular-like (**f**) structures. Scale bars, 100  $\mu\text{m}$ . **g-j**, TEM of day 16 kidney organoids. **g**, Immature podocytes. Scale bar, 5  $\mu\text{m}$ . **h**, A magnified view of the boxed region in **g** showing a detail of podocyte-related structures including the deposition of a basement membrane (bm), and primary (pp) and secondary cell processes (sp). Scale bar, 1  $\mu\text{m}$ . **i**, Epithelial tubular-like cells with brush borders (bb), high mitochondrial (mit) content and tight junctions (tj). Scale bar, 2  $\mu\text{m}$ . **j**, A magnified view of the boxed region in **i** showing a detail of brush borders. Scale bar, 1  $\mu\text{m}$ .



**Fig. 2 | Kidney organoids model human kidney organogenesis in vitro.** **a**, Representation of the coculture of day 5 NPCs with mouse embryonic kidney cells. **b–d**, Bright-field images of reagggregates after 1 d (**b**), 4 d (**c**) and 6 d (**d**) in culture. Scale bars, 500  $\mu$ m. **e**, Immunocytochemistry for PAX8, WT1 and HuNu of the reaggregate in **d**. Scale bar, 250  $\mu$ m. **f**, Magnified views of **d**. Scale bars, 50  $\mu$ m. **g–i**, Modulation of  $\beta$ -catenin signalling in kidney organoids with IWR1 and CHIR inhibitors. **g**, Immunocytochemistry for WT1 and LTL in day 16 kidney organoids with the indicated regimens. Scale bars, 50  $\mu$ m. **h**, Corresponding quantification of the percentage of WT1<sup>+</sup> cells and LTL<sup>+</sup> structures. Data are mean  $\pm$  s.d.  $n=3$  organoids per treatment. One-way analysis of variance with Tukey's post hoc test. For % WT1,  $F(1.009, 2.017) = 213.6$ ,  $P = 0.0045$ ; vehicle versus CHIR,  $**P = 0.0082$ ; CHIR versus IWR1,  $****P = 0.000034$ ; vehicle versus IWR1, n.s., not significant,  $P = 0.9995$ . For % LTL,  $F(1.002, 2.004) = 0.9976$ ,  $P = 0.4232$ , not significant. **i**, Corresponding qPCR analysis (genes are indicated). Data are mean  $\pm$  s.d. (three technical replicates). **j–l**, Energy metabolism profile of kidney organoids maintained in EGM or REGM: kinetic oxygen consumption rate (OCR) response (**j**), inner mitochondrial membrane proton leak and cellular ATP production (**k**) and basal respiration and spare respiratory capacity (**l**). Data are normalized to mitochondrial DNA copy number/sample. Data are mean  $\pm$  s.d.  $n=3$  (EGM) and  $n=2$  (REGM) organoids. **m**, Immunocytochemistry for LTL and PODXL in day 16 kidney organoids under EGM or REGM regimen. Scale bars, 200  $\mu$ m (EGM) and 400  $\mu$ m (REGM). **n**, Corresponding quantification of the percentage of PODXL<sup>+</sup> and LTL<sup>+</sup> structures. Data are mean  $\pm$  s.d.  $n=2$  organoids per condition.

## 262 **Vascularization of kidney organoids using chick** 263 **chorioallantoic membrane (CAM)**


264 Kidney organoids have shown the presence of nascent vascular  
 265 endothelial cells surrounding renal structures, but lack a proper  
 266 vascular pattern<sup>4,9</sup>. Of note, only two independent studies have  
 267 reported in vivo vascularization of either hiPSC-derived NPCs<sup>20</sup>  
 268 or kidney organoids<sup>21</sup> when transplanted under the kidney capsule  
 269 of immunodeficient mice, identifying in both cases host-derived  
 270 vascularization. We decided to explore an alternative approach for  
 271 providing a vascular environment to kidney organoids. We made  
 272 use of the chick CAM, a highly vascularized extraembryonic tissue  
 273 that has been used in tumour angiogenesis research<sup>22,23</sup> and for  
 274 the grafting of biomaterials<sup>24</sup>. More so than other in vivo models,  
 275 such as the mouse, CAM represents a naturally immunodeficient  
 276 environment that offers direct, minimally invasive access to the  
 277 assay site, thereby facilitating the monitoring of the experiments  
 278 in situ. We implanted day 16 kidney organoids into the CAM of  
 279 7-day-old chick embryos, and then maintained them in ovo for 5 d  
 280 (Fig. 3a; Methods). On day 3 of implantation, multiple blood vessels  
 281 from the CAM were macroscopically distinguished throughout  
 282 kidney organoids (Fig. 3b, Supplementary Video 1). The circulation  
 283 of chick blood within kidney organoids was clearly observed after  
 284 5 d (Fig. 3c, Supplementary Video 2). At this stage, in vivo injection  
 285 of dextran-FITC (fluorescein isothiocyanate) into the CAM  
 286 allowed for live imaging of the vasculature, confirming the grafting  
 287 of the organoids into the CAM (Fig. 3d, Supplementary Video 3).  
 288 Compared with in vitro counterparts (Supplementary Fig. 12a),  
 289 CAM-implanted kidney organoids (implanted organoids) exhibited  
 290 glomeruli with an enlarged Bowman's space and tubule-like structures  
 291 with enlarged lumens (Supplementary Fig. 12b,c, magnified  
 292 views). Furthermore, CAM blood vessels (indicated with asterisks  
 293 in Supplementary Fig. 12b,c,d) were found in close vicinity to glomerulus  
 294 structures. Immunofluorescence analysis of consecutive sections  
 295 confirmed the presence of chick blood vessels (labelled with  
 296 *Lens culinaris* agglutinin) within implanted organoids. The latter  
 297 were identified by the expression of the human marker HuNu and  
 298 the presence of glomerulus-like structures (WT1<sup>+</sup>) (Supplementary  
 299 Fig. 12e). Next, we tested the ability of implanted organoids to  
 300 respond to the well known nephrotoxic agent cisplatin. Twenty-four  
 301 hours after injecting cisplatin into the chick vasculature, levels of  
 302 KIM-1 (a marker of renal tubule toxicity) and cleaved CASPASE 3  
 303 (a classical apoptotic marker) were upregulated in proximal tubular  
 304 structures (LTL<sup>+</sup>), compared with specimens injected with a control  
 305 solution (Supplementary Fig. 12f,g).

306 We next analysed semithin (Fig. 3e) and ultrathin sections  
 307 (Fig. 3f–k) of implanted organoids. TEM images revealed the presence  
 308 of aligned podocyte-like cells on one side of a linear basement  
 309 membrane (Fig. 3f–h). Endothelial-like cells were found on the  
 310 opposite side of the basal lamina (Fig. 3f) and, occasionally,  
 311 chicken erythrocytes were observed within the glomerular-like  
 312 structures (Fig. 3h). Podocyte-like cells exhibited multiple microvilli  
 313 on the apical surface and extended primary and secondary cell  
 314 processes on the basal side (Fig. 3f–i, Supplementary Fig. 12h–j).  
 315 Secondary cell processes were bridged by slit diaphragm-like structures  
 316 (Fig. 3g–i, Supplementary Fig. 12h–j). These features, which  
 317 reflect functional differentiation, were not detected in the organoids  
 318 cultured in vitro (Fig. 1g, h). Furthermore, tubular-like cells with  
 319 thick brush borders and high mitochondrial content were observed  
 320 (Fig. 3j,k). Immunofluorescence analysis showed apical localization  
 321 of PODXL in aligned podocyte-like cells situated on the basement  
 322 membrane (LAMININ<sup>+</sup>). Conversely, podocin and NEPH1 localized  
 323 on the podocyte basal side (Fig. 3l). Likewise, CD34<sup>+</sup> endothelial-like  
 324 cells (stained with an antihuman specific CD34 antibody) were  
 325 closely associated with NEPHRIN<sup>+</sup>/PODXL<sup>+</sup> podocyte-like cells  
 326 within glomerulus-like structures in implanted organoids  
 327 (Fig. 3m, Supplementary Fig. 12k). Moreover, endothelial-like cells


(CD31<sup>+</sup>) within glomerulus-like structures (PODXL<sup>+</sup>) coexpressed  
 the human marker HuNu (Fig. 3n). In contrast, for kidney organoids  
 cultured in vitro, CD34<sup>+</sup> endothelial-like cells were not found  
 within glomerulus-like structures (PODXL<sup>+</sup>) (Supplementary  
 Fig. 12l).

## Soft hydrogels enhance the formation of kidney organoids

Mirroring the exact biochemical (for example, site-specific bioactive ligands) and biophysical (for example, extracellular matrix stiffness, fluid flow, oxygen tension) properties of a physiological environment represents an as yet unaffordable technical approach in tissue engineering. By contrast, fabrication of hydrogels with mechanical properties (for example, Young's modulus) similar to native tissues is a key methodology for guiding cellular responses and differentiation<sup>25</sup>. Therefore, we decided to characterize the specific mechanical properties of the CAM (by measuring the Young's modulus, Supplementary Fig. 13a; Methods), which exhibited a stiffness value of about 1 kPa (Supplementary Fig. 13b), representative of an early embryonic microenvironment<sup>26</sup> in which undifferentiated cells are primed for lineage commitment<sup>27</sup>. We next explored whether substrates mimicking a soft microenvironment may favour the generation of kidney organoids, compared with stiffer substrates. Thus, we fabricated functionalized polyacrylamide hydrogels of tunable stiffness (ranging from soft, 1 kPa, to very rigid, 60 kPa) as substrates for hPSC differentiation (Supplementary Fig. 14a; Methods). In comparison with rigid hydrogels, hPSCs grown on soft hydrogels under undifferentiated conditions formed tightly compacted hPSC colonies (ECAD<sup>+</sup>) (Supplementary Fig. 14b), showing reduced nuclear localization of the mechanotransduction marker Yes-associated protein (YAP) (Supplementary Fig. 14c). RNA-Seq analysis of hPSCs revealed that soft hydrogels promoted the expression of genes related to embryo and mesodermal differentiation (Supplementary Table 3), suggesting that a soft milieu may better replicate early stages of embryonic development, during which time counteracting gene regulatory networks control both pluripotency and differentiation ground states<sup>28</sup>. Based on these observations, we hypothesized that using soft hydrogels during the first steps of monolayer differentiation (including PPS and IM induction) may help guide hPSCs toward renal commitment. PPS induction of hPSCs differentiated on soft hydrogels resulted in higher mRNA levels of *T* and *SALL1* markers when compared with rigid conditions (Supplementary Fig. 15a,b). PPS differentiation was also analysed by RNA-Seq, showing that soft hydrogels induced the expression of genes related to transcription regulation and downregulated genes related to extracellular matrix and basement membrane (Supplementary Table 4, Supplementary Fig. 15c). Induction of PPS-committed cells into IM-committed cells (Supplementary Fig. 16a) showed that soft hydrogels promoted increased mRNA levels of the early IM marker *PAX2*, the posterior IM marker *HOXD11*, the anterior IM marker *LHX1*, and *SALL1* when compared with rigid conditions (Supplementary Fig. 16b). Upon differentiation under 3D organotypic culture, IM-committed cells derived on soft hydrogels began to develop RVs one day earlier (at day 7: Supplementary Fig. 16c), and resulted in the generation of more RVs than those derived on rigid hydrogels, as shown by quantitative analysis of PAX2<sup>+</sup> RVs (Fig. 4a,b). Moreover, day 16 kidney organoids from soft conditions developed more WT1<sup>+</sup> glomerulus-like and LTL<sup>+</sup> tubule-like structures than those derived from rigid conditions (Fig. 4c,d), and expressed increased mRNA levels of late-stage nephron (*NPHS1*, *SCNN1B*) and vascularization (*ENDOGLIN*, *VEGFR*) markers (Fig. 4e). TEM of day 16 kidney organoids showed the presence of tubule-like structures containing epithelial cells with prominent brush borders in both soft and rigid conditions (Fig. 4f, Supplementary Fig. 17). Interestingly, soft hydrogels induced the differentiation of podocyte-like cells containing slit diaphragm-like structures between the cell processes (Fig. 4g–i), a podocyte



**Fig. 3 | In vivo vascularization of kidney organoids using chick CAM.** **a**, Methodology for the implantation of day 16 kidney organoids into chick CAM. **b,c**, Macroscopic views of implanted organoids maintained in ovo for 3 d (**b**) and 5 d (**c**). **d**, The implanted organoid in **c** after intravital injection of dextran-FITC through the chick vasculature. Scale bars, 1000  $\mu\text{m}$  (**c,d**). **e**, Semithin sections of a kidney organoid (dashed line) implanted in the CAM mesenchyme (**m**) for 5 d. Magnified views of glomerular (**G**) and tubular (**T**) cells are shown. Scale bars, 200  $\mu\text{m}$ , 100  $\mu\text{m}$  (magnified views). **f-k**, TEM of implanted organoids. Magnified views of the boxed regions in **f,h,j** are shown in **g,i,k**, respectively. **f**, Differentiated podocytes (**p**) extending primary cell processes (**pp**) and apical microvilli (black triangles) are located on one side of the basement membrane (**bm**) and a vascular endothelial cell (**end**) is found on the opposite side. **g**, Slit diaphragm-like structures (red arrows) between secondary cell processes (**sp**). **h**, Aligned podocytes showing primary cell processes and apical microvilli. **er**, chicken erythrocytes. **i**, A detail of the basement membrane and a slit diaphragm-like structure. **j**, Tubular-like cells. **k**, A detail of brush borders (**bb**). Scale bars, 2  $\mu\text{m}$  (**f**), 500 nm (**g**), 10  $\mu\text{m}$  (**h**), 2  $\mu\text{m}$  (**i**), 5  $\mu\text{m}$  (**j**), 1  $\mu\text{m}$  (**k**). **l-n**, Confocal microscopy images of glomerular structures in implanted organoids. **l**, Immunohistochemistry for PODXL, nephrin, NEPH1, podocin and laminin. Scale bars, 25  $\mu\text{m}$ . **m**, Immunohistochemistry for nephrin and CD34. Scale bars, 25  $\mu\text{m}$ , 10  $\mu\text{m}$  (magnified view). **n**, Immunohistochemistry for PODXL, CD31 and the human marker HuNu. Scale bars, 10  $\mu\text{m}$ , 5  $\mu\text{m}$  (magnified view). White arrows indicate endothelial-like cells in close contact with podocyte-like cells (**m,n**).



**Fig. 4 | Soft hydrogels accelerate the differentiation of kidney organoids.** **a**, Immunocytochemistry for PAX2 in RV-stage organoids generated using 1 kPa or 60 kPa hydrogels. Scale bars, 500  $\mu$ m, 150  $\mu$ m (magnified views). **b**, Quantification of **a**. The mean number of RVs and area percentage occupied by RVs were quantified. Data are mean  $\pm$  s.d.  $n=2$  organoids per condition. **c**, Immunohistochemistry for LTL, WT1 and ECAD in day 16 kidney organoids from 1 kPa or 60 kPa. Scale bars, 500  $\mu$ m and 50  $\mu$ m (magnified views). **d**, Quantification of **c**. The percentages of WT1<sup>+</sup> and LTL<sup>+</sup> area were quantified. Data are mean  $\pm$  s.d.  $n=3$  organoids per condition. For WT1<sup>+</sup>  $t(4)=5.8057$ ,  $**P=0.0044$ . For LTL<sup>+</sup>  $t(4)=4.6023$ ,  $*P=0.0100$ . Two-tailed Student's  $t$ -test. **e**, qPCR analysis of day 16 kidney organoids from 1 kPa or 60 kPa (genes are indicated). Data are mean  $\pm$  s.d. (technical replicates). **f-i**, TEM of day 16 kidney organoids from 1 kPa. **f**, Epithelial tubular-like cells with brush borders (bb). **g**, Podocyte-like cells with primary cell processes (pp). **h,i**, Magnified views of **g**. Secondary cell processes (black arrows) with slit diaphragm-like structures (red arrows). Red asterisks, podocyte membrane protrusions. bm, basement membrane. Scale bars, 2  $\mu$ m (**f**), 5  $\mu$ m (**g**), 500 nm (**h**), 200 nm (**i**). **j**, Day 16 kidney organoids from 1 kPa were implanted into the CAM. **k-n**, TEM of implanted kidney organoids from 1 kPa. **k**, Tubular-like cells with brush borders. **l**, Aligned podocyte-like cells extending primary cell processes near endothelial (en) cells and chicken erythrocytes (er). **m,n**, Magnified views of **l**. Secondary cell processes with slit diaphragm-like structures. Scale bars, 2  $\mu$ m (**k**), 10  $\mu$ m (**l**), 1  $\mu$ m (**m**), 200 nm (**n**).

460 differentiation feature that was absent in rigid conditions (Fig. 1g,h,  
461 Supplementary Fig. 17). Considering these findings, day 16 kidney  
462 organoids derived from soft hydrogels were then implanted into  
463 the CAM for 5 days (Fig. 4j). TEM revealed the presence of tubu-  
464 lar epithelial-like cells with brush borders (Fig. 4k) and numerous  
465 glomerular structures containing podocyte-like cells above a dense  
466 basement membrane and in close vicinity to endothelial cells and  
467 chicken erythrocytes (Fig. 4l). Furthermore, induced podocyte-like  
468 cells exhibited secondary cell processes with slit diaphragm-like  
469 structures (Fig. 4m,n).

470

## 471 Outlook

472 The methodology described here reduced the time needed to gener-  
473 ate kidney organoids when compared with previous protocols  
474 by about 30%<sup>1,3-5,9</sup>, leading to the generation of kidney organoids  
475 that transcriptionally resembled second-trimester human fetal  
476 kidneys. This is an improvement over previous findings, in which  
477 kidney organoids clustered with trimester 1 human fetal kid-  
478 neys<sup>9</sup>. Furthermore, here we have shown that kidney organoids  
479 implanted into chick CAM successfully engrafted and were vas-  
480 cularized in ovo, providing a straightforward model for nephro-  
481 toxicity and kidney disease modelling applications. Importantly,  
482 CAM-implanted kidney organoids showed morphological features  
483 that reflect functional differentiation compared with in vitro con-  
484 ditions. When CAM stiffness was mimicked in vitro via compli-  
485 ant hydrogels, hPSCs differentiated on soft substrates (CAM-like)  
486 generated IM-committed cells that showed an accelerated forma-  
487 tion of more RVs and nephron structures than those produced on  
488 rigid substrates. Furthermore, kidney organoids generated from  
489 soft hydrogels exhibited improved differentiation characteristics  
490 when compared with those found under stiffer conditions. These  
491 differentiation features were also enhanced after CAM transplanta-  
492 tion. Overall, the methodology described here paves the way toward  
493 further developing biomimetic approaches that will enhance organ-  
494 oid differentiation (either in vitro or in vivo). These advances will  
495 enable future studies of kidney development and disease.

496

## 497 Online content

498 Any methods, additional references, Nature Research reporting  
499 summaries, source data, statements of data availability and asso-  
500 ciated accession codes are available at [https://doi.org/10.1038/  
501 s41563-019-0287-6](https://doi.org/10.1038/s41563-019-0287-6).

502

503 Received: 5 February 2018; Accepted: 8 January 2019;

504

505

## 506 References

- 507 1. Taguchi, A. et al. Redefining the in vivo origin of metanephric nephron  
508 progenitors enables generation of complex kidney structures from pluripotent  
509 stem cells. *Cell Stem Cell* **14**, 53–67 (2014).
- 510 2. Lam, A. Q. et al. Rapid and efficient differentiation of human pluripotent  
511 stem cells into intermediate mesoderm that forms tubules expressing kidney  
512 proximal tubular markers. *J Am Soc Nephrol*. **25**(6), 1211–1225 (2014).
- 513 3. Morizane, R. et al. Nephron organoids derived from human pluripotent stem  
514 cells model kidney development and injury. *Nat. Biotechnol.* **33**, 1193–1200  
515 (2015).
- 516 4. Freedman, B. S. et al. Modelling kidney disease with CRISPR-mutant kidney  
517 organoids derived from human pluripotent epiblast spheroids. *Nat. Commun.*  
518 **6**, 8715 (2015).
- 519 5. Toyohara, T. et al. Cell therapy using human induced pluripotent stem  
520 cell-derived tenal progenitors ameliorates acute kidney injury in mice.  
521 *Stem Cells Transl. Med.* **4**, 980–992 (2015).
- 522 6. Imberti, B. et al. Renal progenitors derived from human iPSCs engraft and  
523 restore function in a mouse model of acute kidney injury. *Sci. Rep.* **5**, 8826  
524 (2015).
- 525 7. Xia, Y. et al. Directed differentiation of human pluripotent cells to ureteric  
bud kidney progenitor-like cells. *Nat. Cell Biol.* **15**, 1507–1515 (2013).
8. Takasato, M. et al. Directing human embryonic stem cell differentiation  
towards a renal lineage generates a self-organizing kidney. *Nat. Cell Biol.* **16**,  
118–126 (2014).

9. Takasato, M. et al. Kidney organoids from human iPSC cells contain multiple  
lineages and model human nephrogenesis. *Nature* **526**, 564–568 (2015).
10. Taguchi, A., & Nishinakamura, R. Higher-order kidney organogenesis from  
pluripotent stem cells. *Cell Stem Cell* **21**, 730–746 (2017).
11. Musah, S. et al. Mature induced-pluripotent-stem-cell-derived human  
podocytes reconstitute kidney glomerular-capillary-wall function on a chip.  
*Nat. Biomed. Eng.* **1**, (2017).
12. Cruz, N. M. et al. Organoid cystogenesis reveals a critical role of  
microenvironment in human polycystic kidney disease. *Nat. Mater.* **16**,  
1112–1119 (2017).
13. Roost, M. S. et al. KeyGenes, a tool to probe tissue differentiation using a  
human fetal transcriptional atlas. *Stem Cell Rep.* **4**, 1112–1124 (2015).
14. Lindström, N. O. et al. Conserved and divergent features of human and  
mouse kidney organogenesis. *J. Am. Soc. Nephrol.* **29**(3), 785–805 (2018).
15. Unbekandt, M. & Davies, J. A. Dissociation of embryonic kidneys followed by  
reaggregation allows the formation of renal tissues. *Kidney Int.* **77**, 407–416  
(2010).
16. Davies, J. A., Unbekandt, M., Ineson, J., Lusic, M. & Little, M. H. Dissociation  
of embryonic kidney followed by re-aggregation as a method for chimeric  
analysis. *Methods Mol. Biol.* **886**, 135–146 (2012).
17. Lindström, N. O. et al. Integrated  $\beta$ -catenin, BMP, PTEN, and Notch  
signalling patterns in the nephron. *eLife* **3**, e04000 (2014).
18. De Bock, K. et al. Role of PFKFB3-driven glycolysis in vessel sprouting. *Cell*  
**154**, 651–663 (2013).
19. Narayanan, K. et al. Human embryonic stem cells differentiate into functional  
renal proximal tubular-like cells. *Kidney Int.* **83**, 593–603 (2013).
20. Sharmin, S. et al. Human induced pluripotent stem cell-derived podocytes  
mature into vascularized glomeruli upon experimental transplantation. *J. Am.  
Soc. Nephrol.* **27**(6), 1778–1791 (2016).
21. Van den Berg, C. W. et al. Renal subcapsular transplantation of PSC-derived  
kidney organoids induces neo-vasculogenesis and significant glomerular and  
tubular maturation in vivo. *Stem Cell Rep.* **10**, 751–765 (2018).
22. Ribatti, D. Chick embryo chorioallantoic membrane as a useful tool to study  
angiogenesis. *Int. Rev. Cell Mol. Biol.* **270**, 181–224 (2008).
23. Cimpean, A. M., Ribatti, D. & Raica, M. The chick embryo chorioallantoic  
membrane as a model to study tumor metastasis. *Angiogenesis* **11**, 311–319  
(2008).
24. Baiguera, S., Macchiarini, P. & Ribatti, D. Chorioallantoic membrane for in  
vivo investigation of tissue-engineered construct biocompatibility. *J. Biomed.  
Mater. Res. B* **100**, 1425–1434 (2012).
25. Vining, K. H. & Mooney, D. J. Mechanical forces direct stem cell behaviour  
in development and regeneration. *Nat. Rev. Mol. Cell Biol.* **18**, 728–742  
(2017).
26. Przybyla, L., Lakins, J. N. & Weaver, V. M. Tissue mechanics orchestrate  
Wnt-dependent human embryonic stem cell differentiation. *Cell Stem Cell* **19**,  
462–475 (2016).
27. Ahmed, K. et al. Global chromatin architecture reflects pluripotency and  
lineage commitment in the early mouse embryo. *PLoS One* **5**, (2010).
28. Theunissen, T. W. & Jaenisch, R. Mechanisms of gene regulation in human  
embryos and pluripotent stem cells. *Development* **144**, 4496–4509 (2017).

## Acknowledgements

We are grateful to members of the N. Montserrat laboratory for insightful discussions and critical reading of the manuscript. We thank D. O'Keefe and M. Schwarz for administrative help, L. Bardia, A. Lladó and J. Colombelli from the Advanced Digital Microscopy facility at the Institute for Research in Biomedicine for assistance in confocal microscopy imaging and the Electron Cryo-Microscopy Unit at the Scientific and Technological Centers of the University of Barcelona for their technical assistance. We would particularly like to acknowledge the patients and the Fetal Tissue Bank of Vall d'Hebron University Hospital Biobank (PT13/0010/0021), part of the Spanish National Biobanks Network, for its collaboration. This work has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (StG-2014-640525\_REGMAMKID to E.G., P.P., C.T. and N.M. and CoG-616480 to X.T.), the European Commission (project H2020-FETPROACT-01-2016-731957 to X.T. and P.R.-C.), the Spanish Ministry of Economy and Competitiveness/FEDER (BFU2016-77498-P to L.F. and E.M., BFU2015-65074 to X.T., BFU2016-79916-P to P.R.-C., SAF2015-72617-EXP to N.M., SAF2017-89782-R to N.M. and RYC-2014-16242 to N.M.), the Generalitat de Catalunya and CERCA programme (2014-SGR-927 to X.T. and 2017 SGR 1306 to N.M.), Asociación Española contra el Cáncer (AECC CI2016 to L.F. and E.M., LABAE16006 to N.M.). R.O. is supported by an FI fellowship (Generalitat de Catalunya). P.R.-C. is also supported by Obra Social La Caixa. J.C.I.B. is supported by the G. Harold and Leila Y. Mathers Charitable Foundation, the Leona M. and Harry B. Helmsley Charitable Trust (2012-PG-MED002), the Moxie Foundation, the National Institutes of Health (5R21AG055938), the Universidad Católica San Antonio de Murcia and Fundación Dr. Pedro Guillén. C.H.P. is supported by the Bioengineering Excellence of Scientific Training project, cofunded from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 712754 and from the Spanish Ministry of Economy and Competitiveness under the



526 Severo Ochoa grant SEV-2014-0425 (2015–2019). N.M. is also supported by CardioCel  
 527 (TerCel, Instituto de Salud Carlos III). IBEC is the recipient of a Severo Ochoa Award of  
 528 Excellence from MINECO.

### Author contributions

529 E.G. and N.M. conceived and designed the experiments. E.G., P.P., C.T. and C.H.P.  
 530 performed the experiments. E.G., P.P., C.T. and R.O. characterized the cell lines and  
 531 contributed to the protocol design. A.G.-N. and C.H.P. carried out the Seahorse analysis.  
 532 <sup>ORCID</sup> L.C. contributed to the transcriptomic analysis. E.G., P.P., C.T., R.O., L.F., E.M., D.Z.,  
 533 X.T., P.R.-C., J.M.C., J.C.I.B., C.H.P. and N.M. contributed to data interpretation. E.G. and  
 534 <sup>ORCID</sup> N.M. wrote the manuscript. All authors commented on the manuscript and contributed  
 535 to it. N.M. oversaw the project.  
 536  
 537  
 538  
 539  
 540  
 541  
 542  
 543  
 544  
 545  
 546  
 547  
 548  
 549  
 550  
 551  
 552  
 553  
 554  
 555  
 556  
 557  
 558  
 559  
 560  
 561  
 562  
 563  
 564  
 565  
 566  
 567  
 568  
 569  
 570  
 571  
 572  
 573  
 574  
 575  
 576  
 577  
 578  
 579  
 580  
 581  
 582  
 583  
 584  
 585  
 586  
 587  
 588  
 589  
 590  
 591

### Competing interests

The authors declare no competing interests.

### Additional information

Supplementary information is available for this paper at <https://doi.org/10.1038/s41563-019-0287-6>.

Reprints and permissions information is available at [www.nature.com/reprints](http://www.nature.com/reprints).

Correspondence and requests for materials should be addressed to N.M.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s), under exclusive licence to Springer Nature Limited 2019

## 592 Methods

593 **Culture of hPSCs.** All hPSC lines were obtained after the approval of the  
594 Ethics Committee of the Center of Regenerative Medicine in Barcelona and  
595 the Comisión de Seguimiento y Control de la Donación de Células y Tejidos  
596 Humanos del Instituto de Salud Carlos III (project numbers: 0336E/7564/2016;  
597 0336E/5311/2015; 0336E/15986/2016; 0336E/79489/2015; 00336E/20031/2014).  
598 ES[4] hESC and CBIpSsv-4F-40 were obtained from The National Bank of Stem  
599 Cells (ISCIII, Madrid). H1 and H9 hESC lines were purchased at Wicell. All the  
600 lines were maintained in Essential 8 medium (A1517001, Life Technologies) in cell  
601 culture plates coated with 5 µg ml<sup>-1</sup> vitronectin (A14700, Fisher Scientific) with  
602 5% CO<sub>2</sub> at 37 °C. Cells were passaged every 4–6 d.

### 602 hPSC differentiation into renal progenitor cells and generation of 3D kidney

603 **organoids.** hPSCs grown on vitronectin-coated plates were rinsed twice with  
604 PBS (1001–015, Life Technologies) and disaggregated into small cell clusters  
605 with 0.5 mM EDTA (E9884, Sigma). Cells were then seeded onto vitronectin-  
606 coated culture plates at a density of 5 × 10<sup>4</sup>–1.5 × 10<sup>4</sup> cells per cm<sup>2</sup> in Essential 8  
607 medium (day –5). After overnight culture, the differentiation was initiated by  
608 treating hPSCs with 8 µM CHIR (SML1046, Sigma) in advanced RPMI 1640 basal  
609 medium (12633–012, Life Technologies) supplemented with 2 mM L-Glutamax  
610 (35050–038, Life Technologies) and penicillin/streptomycin (penicillin  
611 10,000 U ml<sup>-1</sup>; streptomycin 10,000 µg ml<sup>-1</sup>; 15140122, Life Technologies) for 3 d  
612 (from day –4 to day –1). Next, cultures were treated with 200 ng ml<sup>-1</sup> FGF9 (100–  
613 23B, Peprotech), 1 µM heparin (H3149–10KU, Sigma) and 10 ng ml<sup>-1</sup> activin A  
614 (338-AC-050, Vitro) for 1 d (from day –1 to day 0). Media changes were performed  
615 every day. On day 0, single-cell suspensions were obtained by dissociating cells  
616 with Accumax (07921, Stem Cell Technologies). Cells were then resuspended in  
617 advanced RPMI 1640 basal medium containing 3 µM CHIR, 200 ng ml<sup>-1</sup> FGF9  
618 and 1 µg ml<sup>-1</sup> heparin, placed in 96-well plates (V bottom) at 5 × 10<sup>3</sup> cells per well,  
619 spun down (300 g for 3 min) and maintained in culture for 2 d without medium  
620 change. On day 2, cell spheroids were placed onto Transwells (CLS3460, Sigma)  
621 and cultured in advanced RPMI 1640 basal medium containing 3 µM CHIR,  
622 200 ng ml<sup>-1</sup> FGF9 and 1 µg ml<sup>-1</sup> heparin for another 1 d. On day 3, CHIR was  
623 removed and organoids were maintained in advanced RPMI 1640 basal medium  
624 with 200 ng ml<sup>-1</sup> FGF9 and 1 µg ml<sup>-1</sup> heparin for another 4 d. From day 7 organoids  
625 were maintained in advanced RPMI 1640 basal medium until day 16 unless  
626 otherwise indicated, changing the medium every second day.

627 **Immunocytochemistry.** After a single wash with PBS, samples were fixed with 4%  
628 paraformaldehyde (153799, Anamed) for 20 min at room temperature. Next, samples  
629 were washed twice with PBS and further blocked using Tris-buffered saline (TBS)  
630 with 6% donkey serum (S30, Millipore) and 1% Triton X-100 (T8787, Sigma) for  
631 1 h at room temperature. Samples were then treated overnight at 4 °C with primary  
632 antibodies diluted in antibody dilution buffer consisting of TBS with 6% donkey  
633 serum and 0.5% Triton X-100. After three rinses with antibody dilution buffer,  
634 samples were treated for 4 h at room temperature with fluorescent-conjugated  
635 secondary antibodies (Alexa Fluor (A) 488-, Cy3- or A647-; 1:200). A previous  
636 blocking step with a streptavidin/biotin blocking kit (SP-2002, Vector Labs) was  
637 performed when samples were assayed for biotinylated LTL (B-1325, Vector Labs)  
638 and Alexa Fluor 488-conjugated streptavidin (SA5488, Vector Labs) was used to  
639 detect LTL<sup>+</sup> cells. Nuclei were detected using 4,6-diamidino-2-phenylindole (DAPI;  
640 1:5000, D1306, Life Technologies) for 30 min. For mounting, samples were immersed  
641 in Fluoromount-G (0100-01, Southern Biotech). Image acquisition was carried out  
642 using an SP5 Leica microscope or a Zeiss LSM780 confocal microscope. Primary  
643 antibodies and associated information are provided in Supplementary Table 5.

644 **Electron microscopy.** After fixation of samples with 2.5% glutaraldehyde  
645 containing 1% tannic acid in 0.1 M phosphate buffer (pH 7.4), samples were  
646 postfixed for 1 h at 4 °C with 1% OsO<sub>4</sub> in 0.1 M phosphate buffer. Graded ethanol  
647 series were performed followed by epoxy resin embedding. Toluidine blue staining  
648 was performed in semithin sections before examination using a light microscope.  
649 Then, ultrathin sections were obtained using an EM UC7 ultramicrotome (Leica  
650 Microsystems) and collected on copper grids. 4% uranyl acetate and lead citrate  
651 were then used for staining. Samples were subsequently analysed with a JEM 1230  
652 electron microscope (JEOL).

653 **Total RNA isolation and qPCR with reverse transcription.** TRI Reagent  
654 was employed for total RNA purification following the manufacturer's  
655 recommendations (T9424, Sigma). TURBO DNase inhibitor (AM1907, Ambion)  
656 was used in order to eliminate any residual genomic DNA. Complementary DNA  
657 was synthesized from 1 µg of RNA using a Cloned AMV First-Strand cDNA  
658 synthesis kit (12328, Invitrogen). Quantitative PCR with reverse transcription  
659 (QUANTSTUDIO 5 Applied Biosystems, Thermo Fisher Scientific) was used  
660 to quantify gene expression from cDNAs (25 ng/well) using PowerUp Sybr  
661 Green Master Mix (A25742, Thermo Fisher Scientific). GAPDH or Rplp0 were  
662 used for data normalization. Primer sequences used in this study are listed in  
663 Supplementary Table 6.

664 **Next-generation RNA sequencing.** Sequencing libraries were prepared from 1 µ  
665 g of total RNA (previously isolated using TRI Reagent—T9424, Sigma) using an

666 Illumina TruSeq RNA Sample Prep Kit (catalogue no. FC-122–1001). Sequencing  
667 was carried out to produce between 50 and 60 million paired end reads/sample  
668 using the Illumina HiSeq 2500 platform. Raw sequences were inspected for their  
669 quality using FastQC (version v0.11.5)<sup>29</sup> and trimmed using Skewer (version  
670 0.2.2)<sup>30</sup>. STAR mapper (version 2.5.3a)<sup>31</sup> was used to align the data to the human  
671 reference genome (GRCh38). The option ‘-quantMode’ was employed to count the  
672 number of mapped tags within genes (annotation Gencode v26). On average, 90%  
673 of tags were univocally mapped either to the genomic or to a splice junction. Data  
674 from Chuvá de Sousa Lopes (SRP055513)<sup>13</sup> were analysed in the same way. Read  
675 counts per genes were finally analysed using the R statistical package DESeq2<sup>32</sup>.  
676 Since the two experiments were performed using different techniques (RNA-Seq  
677 and DeepSAGE), we used the ComBat function from the svaseq R package<sup>33</sup> on  
678 rlog-transformed read counts in order to mitigate the batch effect. Scaled rlog  
679 values were then used to calculate the sample-to-sample distance and plotted as  
680 a dendrogram. Data from Little (SRP059518)<sup>9</sup> and McMahon (SRP111183)<sup>14</sup>  
681 were analysed using the same procedure. The package Keygenes<sup>13</sup> was used to  
682 classify every sample according to its similarity to a tissue. Keygenes compares the  
683 transcriptional profiles of test samples with that from organs or cell types from  
684 a training set. In this study, the ‘fetal wo’ training set was used. This training set  
685 contains transcriptional data from 17 fetal organs.

686 **Flow cytometry.** Cells were dissociated using Accumax (07921, Stem Cell  
687 Technologies) for 5 min at 37 °C. Next, cells were resuspended in PBS and  
688 incubated with LIVE/DEAD Fixable Violet stain reagent (L23105, Life  
689 Technologies) (1:1000) for 30 min in the dark. For intracellular staining, a Foxp3/  
690 Transcription Factor Staining Buffer Set (00–5523–00, Labclinics) was used  
691 according to manufacturer's instructions. Briefly, cell suspensions were fixed in  
692 the dark for 30–60 min at room temperature with Foxp3 fixation/permeabilization  
693 working solution. Permeabilization of samples was performed using the  
694 permeabilization buffer for 5 min at room temperature. Blocking was performed  
695 using 2% fetal bovine serum for 15 min. Incubations with conjugated antibodies  
696 were performed for 30 min. The antibodies used were OCT4 conjugated to Alexa  
697 Fluor 488 (560253, BD Pharmingen), brachyury conjugated to allophycocyanin  
698 (IC2085A, R&D Systems) and PAX2 (AF3364, R&D Systems) conjugated to A488  
699 using a Lightning-Link<sup>®</sup> Rapid conjugation kit (322–0010, Innova Biosciences)  
700 following the manufacturer's instructions. Samples were then washed with  
701 permeabilization buffer and resuspended in PBS + 2% fetal bovine serum.  
702 For cell sorting experiments, kidney organoids were stained with fluorescein-  
703 conjugated LTL (FL-1321, Vector Laboratories) as described elsewhere<sup>13</sup>. Kidney  
704 organoids were then dissociated to single cells using Accumax (07921, Stem Cell  
705 Technologies) for 15 min followed by 0.25% (wt/vol) trypsin (25300–054, Life  
706 Technologies) for 15 min at 37 °C. SA3800 software version 2.0.4 (SONY)  
707 was used to acquire flow cytometry samples in the Sony SA3800 spectral cell analyser  
708 (SONY). FACSDiva software version 8.0.1 (BD Biosciences) was used in the FACS  
709 Aria Fusion instrument (BD Biosciences) for cell sorting experiments. FlowJo  
710 software version 10 was used to analyse the data.

### 710 Reaggregation of mouse embryonic kidney cells with hPSC-derived NPCs.

711 These experiments were performed following approval by the Ethics Committee on  
712 Animal Research of the University of Barcelona, Spain (protocol no. OB 391/18).  
713 Reaggregation experiments were carried out as previously described in ref. <sup>16</sup>. In  
714 brief, embryonic kidneys from 11.5–12.5 d post conception were collected from  
715 time-mated pregnant C57BL/6J mice. Kidney rudiments were removed from  
716 mouse embryos by manual dissection under a dissecting microscope. Dissociation  
717 of kidney rudiments into single cells was performed by incubating kidneys with  
718 0.25% (wt/vol) trypsin (25300–054, Life Technologies) for 1–2 min at 37 °C,  
719 followed by quenching of trypsin using complete medium (MEM + 10% fetal  
720 bovine serum + penicillin/streptomycin) and pipetting up and down vigorously  
721 for 30 s to disaggregate kidneys. Day 5 organoids were dissociated into single cells  
722 with Accumax (07921, Stem Cell Technologies). The resultant cell suspensions  
723 were sieved through a 40 µm pore cell strainer. Next, 7.2 × 10<sup>5</sup> mouse kidney cells  
724 were combined with 8 × 10<sup>3</sup> cells from day 5 organoids, placed in a 96-well plate  
725 (V bottom) in complete medium with 10 µM ROCK inhibitor (72304, Stem Cell  
726 Technologies), spun down (300 g for 3 min) and incubated at 37 °C, 5% CO<sub>2</sub> to  
727 allow aggregate formation. After overnight culture, aggregates were placed onto  
728 Transwells (CLS3460, Sigma) and maintained in complete medium at 37 °C and  
729 5% CO<sub>2</sub> for 4–6 d. Medium changes were performed every 48 h.

730 **Nephron patterning assays.** For nephron patterning assays, samples were  
731 cultured in basic differentiation media supplemented with 10 µM DAPT (565770,  
732 Sigma), 3 µM CHIR (SML1046, Sigma) or 5 µM IWR1 (681669, Sigma) from  
733 day 8 to day 16. Organoids were then collected for RNA isolation and fixed with  
734 4% paraformaldehyde for immunocytochemistry.

735 **Seahorse analysis.** Kidney organoids at day 16 of differentiation were resuspended  
736 in warm Seahorse XF Assay Medium (Seahorse Bioscience). Individual organoids  
737 were transferred to an islet plate (one organoid per well) containing 400 µl of  
738 medium per well. After 1 h of incubation at 37 °C, plates were loaded into an XF24  
739 respirometry machine (Seahorse Bioscience). Uncoupled and maximum OCR were

assayed with oligomycin (1  $\mu\text{M}$ ) and FCCP (1.5  $\mu\text{M}$ ). To inhibit complex I- and III-dependent respiration, rotenone (1  $\mu\text{M}$ ) and antimycin A (1  $\mu\text{M}$ ) were used, respectively. OCR represents the oxygen tension and acidification of the medium as a function of time ( $\text{pmol min}^{-1}$ ).

**Implantation of kidney organoids onto chick CAM.** Following animal care guidelines in Spain, no approval was required to perform the experiments described here. Briefly, fertilized white Leghorn chicken eggs were supplied by Granja Gibert. Eggs were placed horizontally in a humidified atmosphere at 38 °C in a Javier Masalles 240 N incubator. After 24 h, 3 ml of albumin was evacuated from the egg using a 18-gauge syringe. At embryonic day 7 (ED 7), a small window was created by cutting the egg shell using a sterile scalpel. Then, day 16 kidney organoids were implanted onto the surface of the CAM (one kidney organoid per egg) by gently scraping the upper CAM layer (avoiding bleeding or visible rupture of capillaries) at the desired implantation site. Egg windows were sealed with conventional plastic tape and incubated for 3–5 additional days (until ED 10–12).

**Intravital imaging of the CAM vasculature.** Under a dissecting microscope, superficial CAM veins were injected with 1  $\text{mg ml}^{-1}$  FITC–dextran (2 MDa) (FD-2000S, Sigma) in PBS using a 30-gauge Hamilton syringe, allowing solutions to circulate for 5 min. Injected volumes were kept at 50  $\mu\text{l}$ . Live imaging was performed using a MZ10 F Leica stereomicroscope equipped with a MC170 HD Leica camera.

**Nephrotoxicity assay.** Chick embryos (ED 14) that contained kidney organoids implanted into the CAM were intravenously injected with desired dosages of cisplatin (P4394, Sigma) using a 30-gauge Hamilton syringe, as previously reported<sup>34</sup>. Specimens injected with control solution (without cisplatin) were used as controls. Eggs were then sealed with conventional plastic tape and incubated overnight at 38 °C. After 24 h, CAM-implanted kidney organoids were collected and analysed.

**Histological analysis and immunohistochemistry on CAM-implanted kidney organoids.** CAM-implanted kidney organoids were harvested at day 5 of the implantation period, fixed in 4% paraformaldehyde at 4 °C overnight and embedded in paraffin. For histological analysis, 5  $\mu\text{m}$  thick sections were stained with haematoxylin and eosin. For immunohistochemistry, antigen retrieval consisting of citrate buffer (pH 6) at 95 °C for 30 min was performed. Samples were then blocked with TBS containing 3% donkey serum and 1% Triton X-100 for 1 h at room temperature. Subsequently, primary antibodies were used overnight at 4 °C in TBS with 3% donkey serum and 0.5% Triton X-100. After three washing steps with TBS containing 3% donkey serum and 0.5% Triton X-100, samples were treated with the appropriate conjugated secondary antibodies (Alexa Fluor 488-, Cy3- or A647-; all 1:200) for 2 h at room temperature. Nuclei were stained with DAPI (1:5000, D1306, Life Technologies) for 10 min. Samples were immersed in Fluoromount-G (0100-01, Southern Biotech). Image acquisition was carried out using a SP5 Leica microscope or a Zeiss LSM780 confocal microscope. Primary antibodies and associated information are provided in Supplementary Table 5.

**Determination of the Young's modulus of the chick CAM.** The ball indentation method was used to assess the Young's modulus ( $E$ ) of the chick CAM, as described in ref.<sup>35</sup>. The indentation depth ( $d$ ) was calculated based on the derivative of fluorescence intensity profile using a custom-made MATLAB code.  $E$  was calculated from the indentation force ( $F$ ),  $d$  and the radius of the ball indenter ( $R$ ). For  $d < 0.3R$ , the Hertz contact mechanics model was used to calculate  $E$  as follows:  $E = [3(1 - \nu^2)F]/4R^{0.5}d^{1.5}$ , where  $\nu$  is the Poisson's ratio of the CAM.

**Fabrication of functionalized polyacrylamide hydrogels.** Glass-bottom dishes were loaded with a solution of acetic acid, 3-(trimethoxysilyl)propyl methacrylate (Sigma) and ethanol (1/1/1/4). Wells were next rinsed three times with 96% ethanol. Different concentrations of acrylamide and bis-acrylamide were combined with a solution containing 0.5% ammonium persulfate, 0.05% tetramethylethylenediamine (Sigma) and 2% fluorescent 200 nm far-red carboxylated nanobeads (Invitrogen). Specifically, concentrations of 5 and 0.04% of acrylamide and bis-acrylamide were used for the softer hydrogels, and 12% and 0.25% of acrylamide and bis-acrylamide for the stiffer hydrogels, resulting in a nominal Young's modulus of 1 kPa and 60 kPa, respectively, according to ref.<sup>36</sup>. The substrates were functionalized as previously described in ref.<sup>37</sup>. Briefly, a drop containing 1  $\text{mg ml}^{-1}$  acrylic acid NHS (A8060, Sigma), 0.2% bis-acrylamide, 0.2% tetramethacrylate (408360, Sigma) and 0.05% (w/v) Irgacure 2959 was added on the surface of the hydrogel and photoactivated under exposure to ultraviolet light for 10 min. Afterwards, functionalized hydrogels were washed with HEPES and PBS and incubated overnight with 50  $\mu\text{g ml}^{-1}$  vitronectin (A14700, Fisher Scientific) at 4 °C.

**Quantification of immunofluorescence images.** A custom-made MATLAB code was used to perform the quantification of immunofluorescence images. For quantification of number and area of RVs, the DAPI image was first smoothed with a mean filter to homogenize the intensity values of the nuclei within an RV.

This image was converted into a binary image after applying an intensity threshold. The binary image was used to segment the RVs by applying a watershed algorithm. From this segmentation, a list containing the area of each RV and the number of RVs was obtained. The entire area of the organoid was identified using the same principle but reducing the threshold for the binary conversion. The percentage of area occupied by RVs was calculated by adding the area of all RVs identified divided by the entire area of the organoid. For quantification of LTL<sup>+</sup> and PODXL<sup>+</sup> structures, the percentage of area occupied by LTL<sup>+</sup> and PODXL<sup>+</sup> structures was calculated using the same procedure as described above. For quantification of WT1<sup>+</sup> cells, the DAPI image was converted into a binary image after applying an intensity threshold. The binary image was used to segment the nuclei by applying a watershed algorithm. All nuclei found were counted. The same procedure was used to identify WT1<sup>+</sup> nuclei. The positive nuclei in WT1 images were divided by the number of DAPI nuclei, giving a percentage of WT1<sup>+</sup> cells for each condition.

**Human kidney material.** Primary human proximal tubular cells were obtained from collaborators at Hospital Clinic de Barcelona, Spain. The procedure was approved by the ethics committee of Hospital Clinic de Barcelona (project no. 2009/5023). Primary renal proximal tubular epithelial cells were obtained in the laboratory of origin as previously described<sup>38</sup>. Human fetal kidney samples included in this study were provided by the Fetal Tissue Bank of Vall d'Hebron University Hospital Biobank (PT13/0010/0021), part of the Spanish National Biobanks Network, and they were processed following standard operating procedures with the appropriate approval of the Ethical and Scientific Committees (project no. 0336E/9934/2015). The gestational age of human fetal kidney samples was determined using ultrasound heel-to-toe and crown-to-rump measurements<sup>39</sup>. Human fetal kidney samples from 13, 16 and 22 weeks of gestation were supplied as whole tissues embedded in OCT (at –80 °C) and as frozen tissue samples for RNA extraction.

**Statistics and reproducibility.** Data are mean  $\pm$  standard deviation (s.d.). Statistical differences between two groups were tested with a two-tailed Student's *t*-test or one-way analysis of variance followed by Tukey's post hoc test. Data were statistically significant if  $P < 0.05$ . Number of replicates ( $n = x$ ), *P* values and degrees of freedom are included in the figure legends. GraphPad Prism version 6.01 software was used for statistical analysis. A table summarizing sample size, number of experiments and statistical test results (when applicable) for each figure panel is also provided as Supplementary Table 7.

For in vitro experiments, two to six organoids were analysed at the times and conditions indicated in each experiment. For ex vivo reaggregation assay, we used one to three pregnant mice (to collect embryonic kidneys from mouse embryos) per experiment. Two or three reaggretates were analysed per experiment. For implantation of organoids into chick CAM in ovo, about 6–22 chicken eggs were used per experiment and about 2–10 implanted kidney organoids were analysed per experiment.

RNA-Seq of kidney organoids during the time course differentiation was performed on six pooled kidney organoids at each time analysed from two independent experiments (Fig. 1c and Supplementary Fig. 9).

For main figures where representative immunofluorescence images are shown, at least  $n = 2$  biologically independent kidney organoids were analysed from independent experiments showing similar results (Fig. 1b,  $n = 2$  organoids; Fig. 2g,  $n = 3$  organoids per treatment; Fig. 2m,  $n = 4$  organoids per culture condition; Fig. 3l,m,  $n = 2$  implanted organoids; Fig. 3n,  $n = 3$  implanted organoids; Fig. 4a,  $n = 2$  organoids per stiffness condition; Fig. 4c,  $n = 3$  organoids per stiffness condition).

For main figures where representative TEM images are shown,  $n = 2$  biologically independent kidney organoids were analysed from independent experiments showing similar results (Fig. 1e–j, Fig. 3e–k, Fig. 4f–i and Fig. 4k–n).

Macroscopic images of kidney organoids after implantation into chick CAM are representative of three independent CAM implantation experiments (Fig. 3b,  $n = 6$  implanted organoids; Fig. 3c,  $n = 10$  implanted organoids; Fig. 3d,  $n = 3$  implanted organoids after dextran–FITC injection).

For supplementary figures, complete information on the number of independent experiments and samples analysed is provided in the corresponding figure legends.

**Reporting Summary.** Further information on research design is available in the Nature Research Reporting Summary linked to this article.

## Code availability

MATLAB codes can be requested from the corresponding author.

## Data availability

RNA-Seq data are publicly available in Gene Expression Omnibus (GEO, <http://www.ncbi.nlm.nih.gov/geo>) under the accession numbers GSE108349, GSE108350 and GSE108351. All remaining datasets supporting the findings described here are available within the article and its supplementary information files. Additionally, data are available from the corresponding author upon reasonable request.

## References

- 724  
725 29. Andrews, S. FastQC: a quality control tool for high throughput sequence  
726 data. <http://www.bioinformatics.babraham.ac.uk/projects/fastqc> (2010).  
727  
728 30. Jiang, H., & Lei, R. & Ding, S. W. & Zhu, S. Skewer: A fast and accurate  
729 adapter trimmer for next-generation sequencing paired-end reads. *BMC*  
730 *Bioinform.* **15**, 182 (2014).  
731 31. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics*  
732 **29**(1), 15–21 (2013).  
733 32. Love, M. I., & Huber, W. & Anders, S. Moderated estimation of fold change and  
734 dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**(12), 550 (2014).  
735 33. Leek, J. T. Svaseq: removing batch effects and other unwanted noise from  
736 sequencing data. *Nucl. Acids Res.* **42**, e161 (2014).  
737 34. Kue, C. S., Tan, K. Y., Lam, M. L. & Lee, H. B. Chick embryo chorioallantoic  
membrane (CAM): an alternative predictive model in acute toxicological  
studies for anti-cancer drugs. *Exp. Anim.* **64**, 129–138 (2015).
35. Lee, D., Rahman, M. M., Zhou, Y. & Ryu, S. Three-dimensional confocal  
microscopy indentation method for hydrogel elasticity measurement.  
*Langmuir* **31**, 9684–9693 (2015).  
36. Yeung, T. et al. Effects of substrate stiffness on cell morphology,  
cytoskeletal structure, and adhesion. *Cell Motil. Cytoskelet.* **60**,  
24–34 (2005).  
37. Przybyla, L., Lakins, J. N., Sunyer, R., Trepas, X. & Weaver, V. M. Monitoring  
developmental force distributions in reconstituted embryonic epithelia.  
*Methods* **94**, 101–113 (2016).  
38. Montserrat, N. et al. Generation of induced pluripotent stem cells from  
human renal proximal tubular cells with only two transcription factors,  
OCT4 and SOX2. *J. Biol. Chem.* **287**, 24131–24138 (2012).  
39. O’Rahilly, R. & Müller, F. Developmental stages in human embryos: revised  
and new measurements. *Cells Tissues Organs* **192**, 73–84 (2010).

# QUERY FORM

<b>Nature Materials</b>	
<b>Manuscript ID</b>	[Art. Id: 287]
<b>Author</b>	Elena Garreta

**AUTHOR:**

The following queries have arisen during the editing of your manuscript. Please answer by making the requisite corrections directly in the e-proofing tool rather than marking them up on the PDF. This will ensure that your corrections are incorporated accurately and that your paper is published as quickly as possible.

<b>Query No.</b>	<b>Nature of Query</b>
Q1:	Please check your article carefully, coordinate with any co-authors and enter all final edits clearly in the eproof, remembering to save frequently. Once corrections are submitted, we cannot routinely make further changes to the article.
Q2:	Note that the eproof should be amended in only one browser window at any one time; otherwise changes will be overwritten.
Q3:	Author surnames have been highlighted. Please check these carefully and adjust if the first name or surname is marked up incorrectly. Note that changes here will affect indexing of your article in public repositories such as PubMed. Also, carefully check the spelling and numbering of all author names and affiliations, and the corresponding email address(es).
Q4:	Please note that after the paper has been formally accepted you can only provide amended Supplementary Information files for critical changes to the scientific content, not for style. You should clearly explain what changes have been made if you do resupply any such files.
Q5:	Please provide units for time in fig. 2j.
Q6:	The symbol 'pp' is mentioned in Figure 3f legend but is not present in the figure. Please indicate its position in the figure.
Q7:	The symbol 'bm' is mentioned in Figure 3f legend but is not present in the figure. Please indicate its position in the figure.
Q8:	Is the insertion of 'Tris-buffered saline' as the definition of 'TBS' correct?
Q9:	Is the insertion of 'fetal bovine serum' as the definition of 'FBS' correct?
Q10:	'A.G.' has been changed to 'A.G.-N.' to match the author name on the title page. Please confirm or correct.
Q11:	'J.C.' has been changed to 'J.M.C.' to match author name on title page. Please confirm or correct.
Q12:	Reference [16,15,14,13] is a duplicate of [9,5,3,1] and hence the repeated version has been deleted. Please check.
Q13:	Please provide the page range or article number for reference 11,26,27,34 and 36.

## Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see [Authors & Referees](#) and the [Editorial Policy Checklist](#).

### Statistical parameters

When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).

n/a Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
- An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated
- Clearly defined error bars  
*State explicitly what error bars represent (e.g. SD, SE, CI)*

Our web collection on [statistics for biologists](#) may be useful.

### Software and code

Policy information about [availability of computer code](#)

#### Data collection

SA3800 version 2.0.4 (SONY) was used for flow cytometry. FACSDiva version 8.0.1 (BD Biosciences) was used for fluorescence-activated cell sorting. Zeiss ZEN 2012 SP5 FP1 version 14.0.11.201 and Leica LAS AF version 2.6.3.8173 were used for confocal microscopy. Cell^D version 3.2 and LAS EZ version 3.4.0 were used for optical microscopy. QuantStudio Real time PCR software was used for qPCR data collection.

#### Data analysis

FlowJo version 10 was used for flow cytometry data analysis. ImageJ version 2006.02.01 was used for image processing. MATLAB version 9.1.0.441655 (R2016b) was used. Matlab analysis procedures that were employed to calculate the young modulus of the CAM and to quantify immunofluorescence images can be made available upon request to the corresponding author. A description of the procedures is available in Methods section of the manuscript. Microsoft excel was used for qPCR and RNA-seq data analysis. Graphpad Prism version 6.01 was used for graphing and statistical analysis. FastQC version 0.11.5, Skewer version 0.2.2, STAR mapper version 2.5.3a and R statistical package DESeq2 were used for RNA-seq data analysis.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

## Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

RNA-seq data are publicly available in Gene Expression Omnibus (GEO, <http://www.ncbi.nlm.nih.gov/geo>) under the accession numbers GSE108349, GSE108350 and GSE108351. All remaining datasets that support the findings of this study are available within the article and its supplementary information files, and from the corresponding author upon reasonable request.

## Field-specific reporting

Please select the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences       Behavioural & social sciences       Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/authors/policies/ReportingSummary-flat.pdf](https://www.nature.com/authors/policies/ReportingSummary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	No statistical methods were used to determine sample size. A minimum of two independent experiments were carried out. For in vitro experiments, 2-6 organoids were analyzed at the time points and conditions indicated in the manuscript for each experiment. Sample size was determined based on previous studies in the field. For ex vivo reaggregation assay, we used 1-3 pregnant mice (to collect embryonic kidneys from mice embryos) per experiment. A number of 2-3 reagggregates were analyzed per experiment. Sample size was determined based on previous studies in the field. For in vivo implantation of organoids, a number of about 6-22 chicken eggs were used per experiment. A number of 2-10 implanted kidney organoids were analyzed per experiment from a total of six experiments. Sample size was determined based on previous studies using tumoral cell lines in the chick CAM. model. All sample sizes, statistical tests and P values are indicated in the figure legends or described in the "Statistics and reproducibility" section of the manuscript.
Data exclusions	No data were excluded from the analyses.
Replication	All experimental findings were reproduced independently at least two times. All attempts at replication were successful. To ensure the reproducibility of our methodology for generating kidney organoids, we used three different human embryonic stem cell (hESC) lines and one human induced pluripotent stem cell line. The number of times that each experiment was repeated is indicated in the figure legends or described in the "Statistics and reproducibility" section of the manuscript.
Randomization	Cells/organoids were chosen at random for measurements within each condition.
Blinding	Blinding was not used during data collection and analysis in experiments that did not involve direct comparisons between groups. Blinding was used for quantitative measurements comparing different conditions in which data analysis was carried out using a custom made code (Fig. 2g,h; Fig. 2m,n; Fig. 4a,b; Fig. 4c,d).

## Reporting for specific materials, systems and methods

### Materials & experimental systems

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> Unique biological materials
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology
<input type="checkbox"/>	<input checked="" type="checkbox"/> Animals and other organisms
<input checked="" type="checkbox"/>	<input type="checkbox"/> Human research participants

### Methods

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input type="checkbox"/>	<input checked="" type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

## Antibodies used

Antibodies and other staining reagents used for immunocytochemistry/immunohistochemistry:  
 OCT4 (Santa Cruz, Cat# sc-5279, clone C-10, Lot# L2216, Dilution 1:25);  
 Nanog (R&D Systems, Cat# A F1997, polyclonal, Lot# KJ0616121, Dilution 1:25);  
 YAP (Santa Cruz, Cat# sc-101199, clone 63.7, Lot# I0315, Dilution 1:200);  
 Brachyury (R&D Systems, Cat# AF2085, polyclonal, Lot# KQP031611, Dilution 1:100);  
 PAX2 (R&D Systems, Cat# AF3364, polyclonal, Lot# XOT0215072, Dilution 1:20);  
 SALL1 (R&D Systems, Cat# PP-K9814-00, clone K9814, Lot# A-3, Dilution 1:100);  
 WT1 (Abcam, Cat# ab89901, clone CAN-R9(IHC)-56-2, Lot# GR177328-54, Dilution 1:100);  
 OSR1 (Abnova, Cat# H00130497-M04, clone 3F3, Lot# DB041-3F3, Dilution 1:25);  
 LHX1 (Developmental Studies Hybridoma Bank, Cat# 4F2-s, clone 4F2, Dilution 1:50);  
 SIX2 (Proteintech, Cat# 11562-1-AP, polyclonal, Dilution 1:500);  
 PAX8 (Proteintech, Cat# 10336-1-AP, polyclonal, Dilution 1:500);  
 ECAD (BD Bioscience, Cat# 610181, clone 36/E-cadherine, Lot# 7187865, Dilution 1:50);  
 PODXL (R&D Systems, Cat# BAF1658, polyclonal, Lot# JLV0112111, Dilution 1:25);  
 HNF1 $\beta$  (Santa Cruz, Cat# sc-7411, clone C-20, Lot# B0116, Dilution 1:100);  
 BRN1 (Santa Cruz, Cat# sc-6028-R, clone C-17, Lot# J2512, Dilution 1:200);  
 NEPHRIN (R&D Systems, Cat# AF4269, polyclonal, Lot# ZMU0114031, Dilution 1:300);  
 KIM1 (R&D Systems, Cat# AF1750, polyclonal, Lot# JTB0317031, Dilution 1:300);  
 cleaved Caspase-3 (Cell Signalling, Cat# 9661S, clone D175, Lot# 45, Dilution 1:200);  
 CD34 (Abcam, Cat# ab8536, cloneQBEND-10, Lot# GR49632-21, Dilution 1:200);  
 CD31 (Abcam, Cat# ab28364, polyclonal, Lot# GR31176844-16, Dilution 1:50);  
 HuNu (Abcam, Cat# ab191181, clone 235-1, Lot# GR3185051-2, Dilution 1:100);  
 Uromodulin (UMOD) (R&D Systems, Cat# AF5144, polyclonal, Lot# CBRF0114081, Dilution 1:50);  
 Aquaporin 1 (AQP1) (Santa Cruz, Cat# sc-20810, clone H-55, Lot# C1815, Dilution 1:50);  
 SLC3A1 (Sigma, Cat# HPA038360, polyclonal, Lot# R35388, Dilution 1:100);  
 Laminin (Sigma, Cat# L9393, polyclonal, Lot# O28M4890V, Dilution 1:50);  
 PODOCIN (Sigma, Cat# P0372, polyclonal, Lot# 064M4780, Dilution 1:50);  
 NEPH1 (Santa Cruz, Cat# sc-373787, clone F-6, Lot# A0313, Dilution 1:50);  
 SGLT2 (Abcam, Cat# ab37296, polyclonal, Lot# GR320725-7, Dilution 1:100);  
 Sodium potassium ATPase (NaK) (Abcam, Cat# ab209299, clone ED1845Y, Lot# GRZ64184-1, Dilution 1:200);  
 Biotinylated Lotus Tetragonolobus Lectin (LTL) (Vector Laboratories, Cat# B-1325, Lot# ZC2428, Dilution 1:200);  
 Biotinylated Lens Culinaris Agglutinin (LCA) (Vector Laboratories, Cat# B-1045, Lot# ZC1221, Dilution 1:500);  
 Alexa Fluor 488-conjugated streptavidin (Vector Laboratories, Cat# SA5488, Lot# ZD0313, Dilution: 1:50);

Antibodies and other staining reagents used for flow cytometry:

Fluorescein labeled LTL (Vector Laboratories, Cat# FL-1321, Lot# ZC0914, Dilution: 1:500);  
 OCT4 conjugated to Alexa Fluor-488 (BD Pharmigen, Cat# 560253, Lot# 7110598, Dilution: 20  $\mu$ l/test);  
 Alexa Fluor 488 Mouse IgG1k isotype control (BD Pharmigen, Cat# 557721, Lot# 7082749, Dilution: 5  $\mu$ l/test);  
 Brachyury conjugated to allophycocyanin (APC) (R&D Systems, Cat# IC2085A, Lot# ADUQ0216041, Dilution: 10  $\mu$ l/test);  
 Goat IgG APC-conjugated antibody (R&D Systems, Cat# IC108A, Lot# AAOE0516031, Dilution: 10  $\mu$ l/test);  
 PAX2 conjugated to A488 using the Lightning-Link<sup>®</sup> Rapid conjugation kit (322-0010, Innova Biosciences) (R&D Systems, Cat# AF3364, Lot# XOT0215072, Dilution: 1:200);  
 Normal Goat IgG Alexa Fluor<sup>®</sup> 488-conjugated Control (R&D Systems, Cat# IC108G, Lot# ABWO41607, Dilution: 5  $\mu$ l/test);  
 LIVE/DEAD Fixable Violet stain reagent (Life Technologies, Cat# L23105, Dilution: 1:1000)

Information of all antibodies / staining reagents is provided in the Methods section or Supplementary information of the manuscript.

## Validation

Antibody validations for the species and assay used were performed by antibody suppliers as described in the manufacture's web page, or were published in previous studies. Relevant articles are:

Xia Y, Nivet E, Sancho-Martinez I, Gallegos T, Suzuki K, Okamura D, Wu MZ, Dubova I, Esteban CR, Montserrat N, Campistol JM, Izpisua Belmonte JC. Directed differentiation of human pluripotent cells to ureteric bud kidney progenitor-like cells. *Nat Cell Biol.* 2013 Dec;15(12):1507-15. doi: 10.1038/ncb2872. Epub 2013 Nov 17. PubMed PMID: 24240476. (OCT4, OSR1, SIX2: human, immunofluorescence).

Martí M, Mulero L, Pardo C, Morera C, Carrió M, Laricchia-Robbio L, Esteban CR, Izpisua Belmonte JC. Characterization of pluripotent stem cells. *Nat Protoc.* 2013 Feb;8(2):223-53. doi: 10.1038/nprot.2012.154. Epub 2013 Jan 10. PubMed PMID: 23306458. (OCT4, Nanog, Brachyury: human, immunofluorescence).

Elosegui-Artola A, Andreu I, Beedle AEM, Lezamiz A, Uroz M, Kosmalska AJ, Oria R, Kechagia JZ, Rico-Lastres P, Le Roux AL, Shanahan CM, Trepas X, Navajas D, Garcia-Manyes S, Roca-Cusachs P. Force Triggers YAP Nuclear Entry by Regulating Transport across Nuclear Pores. *Cell.* 2017 Nov 30;171(6):1397-1410.e14. doi: 10.1016/j.cell.2017.10.008. Epub 2017 Oct 26. PubMed PMID: 29107331. (YAP: human, immunofluorescence)

Morizane R, Lam AQ, Freedman BS, Kishi S, Valerius MT, Bonventre JV. Nephron organoids derived from human pluripotent stem cells model kidney development and injury. *Nat Biotechnol.* 2015 Nov;33(11):1193-200. PubMed PMID: 26458176; PubMed Central PMCID: PMC4747858. (SALL1, LHX1, SIX2, PAX8, PODXL, HNF1 $\beta$ , BRN1, KIM1, LTL: human, immunofluorescence)

Takasato M, Er PX, Chiu HS, Maier B, Baillie GJ, Ferguson C, Parton RG, Wolvetang EJ, Roost MS, Chuva de Sousa Lopes SM, Little MH. Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis. *Nature.* 2015 Oct



22;526(7574):564-8. doi: 10.1038/nature15695. Epub 2015 Oct 7. Erratum in: Nature. 2016 Aug 11;536(7615):238. PubMed PMID: 26444236. (SIX2, ECAD, NEPHRIN, Caspase-3, LTL: human, immunofluorescence).

Sharmin S, Taguchi A, Kaku Y, Yoshimura Y, Ohmori T, Sakuma T, Mukoyama M, Yamamoto T, Kurihara H, Nishinakamura R. Human Induced Pluripotent Stem Cell-Derived Podocytes Mature into Vascularized Glomeruli upon Experimental Transplantation. *J Am Soc Nephrol*. 2016 Jun;27(6):1778-91. doi: 10.1681/ASN.2015010096. Epub 2015 Nov 19. PubMed PMID: 26586691; PubMed Central PMCID: PMC4884101. (CD31: human, immunofluorescence).

Cai G, Lai B, Hong H, Lin P, Chen W, Zhu Z, Chen H. Effects of cryopreservation on excretory function, cellular adhesion molecules and vessel lumen formation in human umbilical vein endothelial cells. *Mol Med Rep*. 2017 Jul;16(1):547-552. doi: 10.3892/mmr.2017.6664. Epub 2017 May 31. PubMed PMID:28586042; PubMed Central PMCID: PMC5482135. (CD34: human, immunofluorescence).

Lei P, Ding D, Xie J, Wang L, Liao Q, Hu Y. Expression profile of Twist, vascular endothelial growth factor and CD34 in patients with different phases of osteosarcoma. *Oncol Lett*. 2015 Jul;10(1):417-421. Epub 2015 May 20. PubMed PMID: 26171042; PubMed Central PMCID: PMC4487166. (CD34: human, immunofluorescence).

Cruz NM, Song X, Czerniecki SM, Gulieva RE, Churchill AJ, Kim YK, Winston K, Tran LM, Diaz MA, Fu H, Finn LS, Pei Y, Himmelfarb J, Freedman BS. Organoid cystogenesis reveals a critical role of microenvironment in human polycystic kidney disease. *Nat Mater*. 2017 Nov;16(11):1112-1119. doi: 10.1038/nmat4994. Epub 2017 Oct 2. PubMed PMID: 28967916; PubMed Central PMCID: PMC5936694. (NEPHRIN, PODXL, LTL, Fluorescein labeled LTL: human, immunofluorescence).

Lindström NO, Tran T, Guo J, Rutledge E, Parvez RK, Thornton ME, Grubbs B, McMahon JA, McMahon AP. Conserved and Divergent Molecular and Anatomic Features of Human and Mouse Nephron Patterning. *J Am Soc Nephrol*. 2018 Mar;29(3):825-840. doi: 10.1681/ASN.2017091036. Epub 2018 Feb 15. PubMed PMID: 29449451; PubMed Central PMCID: PMC5827611. (Pax2, WT1, SLC3A1, Uromodulin: human, immunofluorescence).

Vedula EM, Alonso JL, Arnaout MA, Charest JL. A microfluidic renal proximal tubule with active reabsorptive function. *PLoS One*. 2017 Oct 11;12(10): e0184330. doi: 10.1371/journal.pone.0184330. eCollection 2017. PubMed PMID: 29020011; PubMed Central PMCID: PMC5636065. (SGLT2: human, immunofluorescence).

Kang KJ, Lee MS, Moon CW, Lee JH, Yang HS, Jang YJ. In Vitro and In Vivo Dentinogenic Efficacy of Human Dental Pulp-Derived Cells Induced by Demineralized Dentin Matrix and HA-TCP. *Stem Cells Int*. 2017; 2017:2416254. doi:10.1155/2017/2416254. Epub 2017 Jun 28. PubMed PMID: 28761445; PubMed Central PMCID: PMC5518496. (HuNu: human, immunofluorescence).

Jilani SM, Murphy TJ, Thai SN, Eichmann A, Alva JA, Iruela-Arispe ML. Selective binding of lectins to embryonic chicken vasculature. *J Histochem Cytochem*. 2003 May;51(5):597-604. PubMed PMID: 12704207. (Biotinylated Lens Culinaris Agglutinin: chicken, immunofluorescence).

Yamaguchi S, Morizane R, Homma K, Monkawa T, Suzuki S, Fujii S, Koda M, Hiratsuka K, Yamashita M, Yoshida T, Wakino S, Hayashi K, Sasaki J, Hori S, Itoh H. Generation of kidney tubular organoids from human pluripotent stem cells. *Sci Rep*. 2016 Dec 16;6: 38353. doi: 10.1038/srep38353. PubMed PMID: 27982115; PubMed Central PMCID: PMC5159864. (Aquaporin 1: human, immunofluorescence).

Fagerberg L, Hallström BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, Habuka M, Tahmasebpoor S, Danielsson A, Edlund K, Asplund A, Sjöstedt E, Lundberg E, Szigarty CA, Skogs M, Takanen JO, Berling H, Tegel H, Mulder J, Nilsson P, Schwenk JM, Lindskog C, Danielsson F, Mardinoglu A, Sivertsson A, von Feilitzen K, Forsberg M, Zwahlen M, Olsson I, Navani S, Huss M, Nielsen J, Ponten F, Uhlén M. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. *Mol Cell Proteomics*. 2014 Feb;13(2):397-406. doi: 10.1074/mcp.M113.035600. Epub 2013 Dec 5. PubMed PMID: 24309898; PubMed Central PMCID: PMC3916642. (PODOCIN: human, immunofluorescence).

Wong KG, Ryan SD, Ramnarine K, Rosen SA, Mann SE, Kulick A, De Stanchina E, Müller FJ, Kacmarczyk TJ, Zhang C, Betel D, Tomishima MJ. CryoPause: A New Method to Immediately Initiate Experiments after Cryopreservation of Pluripotent Stem Cells. *Stem Cell Reports*. 2017 Jul 11;9(1):355-365. doi: 10.1016/j.stemcr.2017.05.010. Epub 2017 Jun 8. PubMed PMID: 28602613; PubMed Central PMCID: PMC5511100. (Brachyury conjugated to allophycocyanin (APC): human, flow cytometry).

## Eukaryotic cell lines

Policy information about [cell lines](#)

Cell line source(s)

Human pluripotent stem cell lines:

All the human pluripotent stem cell lines used in this study were obtained after the approval of the Ethics Committee of the CMRB and the approval of the Comisión de Seguimiento y Control de la Donación de Células y Tejidos Humanos del Instituto de Salud Carlos III (project numbers: 0336E/7564/2016; 0336E/5311/2015; 0336E/15986/2016; 0336E/79489/2015; 00336E/20031/2014). ES[4] hESC and CBiPSsv-4F-40 were obtained from The National Bank of Stem Cells (ISCIII, Madrid). H1 and H9 hESC lines were purchased at Wicell.

Information on cell line sources used in this study is also provided in the Methods section of the manuscript.

Human kidney material:

Primary human proximal tubular cells were obtained from collaborators at Hospital Clinic de Barcelona, Spain. The ethics committee of Hospital Clinic de Barcelona approved the procedure, and signed consent forms are available upon request (project number: 2009/5023). Isolation of primary renal proximal tubular epithelial cells was performed as previously described. Briefly, tubular cells were prepared from renal tissue after nephrectomy. Cortical renal tissue was digested in

Iscove's modified Dulbecco's medium with 1% collagenase IV (Invitrogen) for 1h under shaking. Cell suspension was placed on a pre-cooled Percoll density gradient solution (Amersham Biosciences) and centrifuged for 40 min at 4 °C at 16,000 rpm (gradient with densities between 1.019 and 1.139 g/ml was generated). The cell fraction between 1.05 and 1.076 g/ml was collected and cells were plated on plastic plates with DMEM (Invitrogen) supplemented with 10% fetal bovine serum (FBS; Invitrogen), Glutamax (1 mM), penicillin/streptomycin, and nonessential amino acids (100 µM).

Relevant reference:

Montserrat N, Ramírez-Bajo MJ, Xia Y, Sancho-Martinez I, Moya-Rull D, Miquel-Serra L, Yang S, Nivet E, Cortina C, González F, Izpisua Belmonte JC, Campistol JM. Generation of induced pluripotent stem cells from human renal proximal tubular cells with only two transcription factors, OCT4 and SOX2. *J Biol Chem.* 2012 Jul 13;287(29):24131-8.

Human fetal kidney samples included in this study were provided by the Fetal Tissue Bank of Vall d'Hebron University Hospital Biobank (PT13/0010/0021), integrated in the Spanish National Biobanks Network and they were processed following standard operating procedures with the appropriate approval of the Ethical and Scientific Committees (project number: 0336E/9934/2015). Human fetal kidney samples from 13, 16 and 22 weeks of gestation were supplied as whole tissues embedded in OCT (at -80 °C) and as frozen tissue samples for RNA extraction.

Information on human kidney material used in this study is also provided in the Methods section of the manuscript.

#### Authentication

Human pluripotent stem cell lines:

Human embryonic stem cells (ES4, H1 and H9 lines) and human induced pluripotent stem cells (CBiPSsv-4F-40 line) were authenticated in their lab of origin through the expression of pluripotency-associated markers.

Human kidney material:

Primary human proximal epithelial cells were authenticated in the lab of origin for the expression of specific proximal tubular cell markers, as previously reported.

Relevant reference:

Montserrat N, Ramírez-Bajo MJ, Xia Y, Sancho-Martinez I, Moya-Rull D, Miquel-Serra L, Yang S, Nivet E, Cortina C, González F, Izpisua Belmonte JC, Campistol JM. Generation of induced pluripotent stem cells from human renal proximal tubular cells with only two transcription factors, OCT4 and SOX2. *J Biol Chem.* 2012 Jul 13;287(29):24131-8.

The gestational age of human fetal kidney samples was determined per guidelines specified by the American College of Obstetricians and Gynecologists using ultrasound heel-to-toe, and crown-to-rump measurements.

Relevant reference:

O'Rahilly R, Müller F: Developmental stages in human embryos: Revised and new measurements. *Cells Tissues Organs* 192: 73–84, 2010.

#### Mycoplasma contamination

All cell lines tested negative for mycoplasma contamination.

#### Commonly misidentified lines (See [ICLAC](#) register)

No commonly misidentified cell lines were used.

## Animals and other organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research

#### Laboratory animals

For mice experiments:

Animal care and experiments were carried out according to protocols approved by the Ethics Committee on Animal Research of the University of Barcelona, Spain (protocol number: OB 391/18). Embryonic kidneys from 11.5-12.5 days post conception (d.p.c) were collected from time-mated pregnant C57BL/6J mice.

For chicken experiments:

According to animal care guidelines in Spain, no approval was necessary to perform the experiments described herein. Fertilized white Leghorn chicken eggs were provided by Granja Gibert, rambla Regueral, S/N, 43850 Cambrils, Spain.

#### Wild animals

The study does not involve wild animals.

#### Field-collected samples

The study does not involve samples collected from the field.

## Flow Cytometry

#### Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

#### Methodology

##### Sample preparation

Cells were dissociated using accumax (07921, Stem Cell Technologies) for 5 min at 37°C and stained according to a standard

Sample preparation	methodology described in the Methods section of the manuscript. Kidney organoids were stained according to a standard methodology described in the Methods section of the manuscript. Kidney organoids were then dissociated to single cells using accutax (07921, Stem Cell Technologies) for 15 min followed by 0.25% (wt/vol) trypsin (25300-054, Life Technologies) for 15 min at 37°C.
Instrument	Sony SA3800 spectral cell analyzer (SONY) was used to acquire flow cytometry samples (Supplementary Fig.1b and Supplementary Fig.2b), whereas FACSAria Fusion instrument (BD Biosciences) was used for cell sorting experiments (Supplementary Fig. 5b).
Software	SA3800 software version 2.0.4 (SONY) was used to acquire flow cytometry samples in the Sony SA3800 spectral cell analyzer (SONY), whereas FACSDiva software version 8.0.1 (BD Biosciences) was used in the FACS Aria Fusion instrument (BD Biosciences) for cell sorting experiments. FlowJo software version 10 was used to analyze these data.
Cell population abundance	The abundance of the relevant cell populations was based on the expression of specific nuclear and surface markers that were analyzed by immunofluorescence and quantitative RT-PCR.
Gating strategy	<p>Supplementary Fig. 1b: For assessment of OCT4 and T staining, cells were first gated on a SS-A versus FS-A plot, the population from which was then gated on the LIVE/DEAD negative population (LIVE/DEAD versus FS-A plot), the population from which was then analyzed on a plot of T-APC versus OCT4-A488.</p> <p>Supplementary Fig. 2b: For assessment of PAX2 staining, cells were first gated on a SSC-A versus FSC-A plot, the population from which was then gated on the LIVE/DEAD negative population (LIVE/DEAD versus FSC-A plot), the population from which was then analyzed on a plot of SSC-A versus PAX2-A488.</p> <p>Supplementary Fig. 5b: For fluorescence activated cell sorting of LTL-FITC positive and negative cell fractions, cells were first gated on a SSC-A versus FSC-A plot, the population from which was then gated on singlets (FSC-W versus FSC-A plot), the population from which was then gated on the LIVE/DEAD negative population (LIVE/DEAD versus FSC-A plot), the population from which was then analyzed on a plot of autofluorescence (AU) versus LTL-FITC.</p>

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.